The Office of the Chief Scientist will finance 30-50% of the program, with the company financing the rest.
Exalenz Bioscience Ltd. (TASE:EXEN) has obtained Office of the Chief Scientist approval for a NIS 8.9 million R&D program. The Office of the Chief Scientist will finance 30-50% of the program, with the company financing the rest.
Exalenz will develop a diagnostic kit for illnesses of the liver, pancreas, digestive tract, and other diseases.
Published by Globes [online], Israel business news - www.globes-online.com - on March 28, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010